Stock Research: Daewoong Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Daewoong Pharmaceutical

KSC:069620 KR7069620003
75
  • Value
    55
  • Growth
    89
  • Safety
    Safety
    32
  • Combined
    75
  • Sentiment
    89
  • 360° View
    360° View
    75
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Daewoong Pharma manufactures and distributes pharmaceuticals. It operates in the pharmaceutical industry, producing drugs for various treatments. The company distributes its products domestically and internationally. In the last fiscal year, the company had a market cap of $1,374 million, profits of $497 million, and revenue of $963 million. The number of employees is not available.

more
Index
KOSPI
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
55 34 40 27
Growth
89 98 43 23
Safety
Safety
32 13 14 8
Sentiment
89 94 67 20
360° View
360° View
75 30 23 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
79 88 93 5
Opinions Change
50 50 50 4
Pro Holdings
n/a 62 38 63
Market Pulse
59 84 61 86
Sentiment
89 94 67 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
55 34 40 27
Growth
89 98 43 23
Safety Safety
32 13 14 8
Combined
75 1 12 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
46 65 74 52
Price vs. Earnings (P/E)
61 44 53 23
Price vs. Book (P/B)
28 24 31 24
Dividend Yield
69 27 26 21
Value
55 34 40 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
51 59 52 47
Profit Growth
37 100 87 40
Capital Growth
94 87 40 27
Stock Returns
78 80 13 51
Growth
89 98 43 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
25 30 13 14
Refinancing
23 8 5 19
Liquidity
76 40 41 14
Safety Safety
32 13 14 8

Similar Stocks

Discover high‑ranked alternatives to Daewoong Pharmaceutical and broaden your portfolio horizons.

NGK Insulators

TYO:5333
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Brother Industries

TYO:6448
Country: Japan
Industry: Technology Hardware & Peripherals
Size: X-Large
Full Stock Analysis

Hyundai Home Shopping Network

KSC:057050
Country: South Korea
Industry: Internet Retail
Size: Medium
Full Stock Analysis

DB HiTek

KSC:000990
Country: South Korea
Industry: Semiconductors
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: